Caribou Biosciences EPS CRBU

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Caribou Biosciences' earnings per share was −$1.08 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.24.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.24	n/a	−$1.08
Q1 FY26	Mar 31, 2026	−$0.26	n/a	−$1.42
Q4 FY25	Dec 31, 2025	−$0.28	n/a	−$1.59
Q3 FY25	Sep 30, 2025	−$0.30	n/a	−$1.70
Q2 FY25	Jun 30, 2025	−$0.58	n/a	−$1.78
Q1 FY25	Mar 31, 2025	−$0.43	n/a	−$1.62
Q4 FY24	Dec 31, 2024	−$0.39	n/a	−$1.65
Q3 FY24	Sep 30, 2024	−$0.38	n/a	−$1.65
Q2 FY24	Jun 30, 2024	−$0.42	n/a	−$1.39
Q1 FY24	Mar 31, 2024	−$0.46	n/a	−$1.45
Q4 FY23	Dec 31, 2023	−$0.39	n/a	−$1.45
Q3 FY23	Sep 30, 2023	−$0.12	n/a	−$1.50

Companies in Healthcare nearest Caribou Biosciences' size, closest first, today.

Company	EPS, 12 months	Growth
CRBUCaribou Biosciences	−$1.08
APTAlpha Pro Tech	$0.41	+24% a year
SPROSpero Therapeutics	$0.11
ATNMActinium Pharmaceuticals	$0.36
LFVNLifevantage	$0.40	−46% a year
NEPHNephros	$0.16	+33% a year
ICCCImmucell	$0.08	−58% a year
KEQUKewaunee Scientific	$2.76	−33% a year
PDEXPro DEX	$4.11	+52% a year
PLXProtalix BioTherapeutics	$0.23	+283% a year
NATRNatures Sunshine Products	$1.01	+36% a year
Peer median	$0.38